96449-69-3

Basic information

• Product Name: 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE
• Synonyms: 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE;OTAVA-BB 1084626;4-(Hydroxymethyl)-1-benzylpyrrolidin-2-one;1-Benzyl-4-(hydroxyMethyl)-2-pyrrolidinone
• CAS NO: 96449-69-3
• Molecular Formula: C₁₂H₁₅NO₂
• Molecular Weight: 205.26
• Mol File: 96449-69-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 411.3°Cat760mmHg
• Flash Point: 202.5°C
• Appearance: /
• Density: 1.185g/cm³
• Vapor Pressure: 1.68E-07mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE(96449-69-3)
• EPA Substance Registry System: 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE(96449-69-3)

Safety Data

• Hazardous Substances Data: 96449-69-3(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-(hydroxymethyl)pyrrolidin-2-one is a chemical compound with the molecular formula C14H17NO2. It is a pyrrolidin-2-one derivative with a benzyl group attached to the 1-position and a hydroxymethyl group attached to the 4-position. 1-BENZYL-4-(HYDROXYMETHYL)PYRROLIDIN-2-ONE has potential pharmaceutical applications due to its unique structure and properties. It may be used in the development of new drugs or as a building block in organic synthesis. Additionally, it could also be used in research settings to study its effects and potential uses in medicinal chemistry.

InChI:InChI=1/C12H15NO2/c14-9-11-6-12(15)13(8-11)7-10-4-2-1-3-5-10/h1-5,11,14H,6-9H2

Upstream product

• 100-46-9 benzylamine 
• 617-52-7 Dimethyl itakonate 
• 5733-86-8 1-benzyl-5-oxopyrrolidine-3-carboxylic acid 
• 51535-00-3 methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate 

Downstream Products

• 1033718-06-7 cis-tert-butyl N-[4-(fluoromethyl)pyrrolidin-3-yl]carbamate 
• 1396762-87-0 C₂₄H₄₁NO₆Si 
• 1396762-85-8 C₂₂H₃₅NO₄Si 
• 1396762-81-4 C₁₆H₂₂N₂O₂ 
• 1396762-80-3 C₂₉H₄₂N₂O₂Si 
• 1396762-78-9 2-benzyl-4-((tert-butyldimethylsilanyl)oxymethyl)-2-aza-spiro[4.4]non-7-en-1-one 
• 1396762-76-7 3,3-diallyl-1-benzyl-4-((tert-butyldimethylsilanyl)oxymethyl)-pyrrolidin-2-one 

Relevant articles and documents

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

A method for preparing west Naira Tanzania

The invention discloses a preparation method for nebracetam, and belongs to the technical field of medical chemistry. The key points of the technical scheme of the invention are as follows: the preparation method for the nebracetam comprises the following steps: performing Michael addition reaction and intramolecular cyclization on dimethyl itaconate and benzylamine serving as raw materials to obtain 1-benzyl-5-oxopyrrolidin-3-carboxylic methyl ester; reducing the 1-benzyl-5-oxopyrrolidin-3-carboxylic methyl ester by sodium borohydride to obtain 1-benzyl-4-hydroxymethyl-pyrrolidine-2-keton; performing methyl sulfonylation on the 1-benzyl-4-hydroxymethyl-pyrrolidine-2-keton to obtain 1-benzyl-5-oxopyrrolidin-3-carboxylic methanesulfonate; finally, performing ammonification and reduction on the 1-benzyl-5-oxopyrrolidin-3-carboxylic methanesulfonate by using ammonia water to obtain the nebracetam. The preparation method is simple in preparation process, easy to control and high in target product yield, and meets the requirement for green chemistry.

Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1

Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in su